We also report significant efficacy of MK-1775 (Wee1 inhibitor) as a monotherapy and in combination with avapritinib in an engineered GIST cell line driven by an activating PDGFRA D842V mutation. Here, WEE1 is linked to gastrointestinal stromal tumor.